TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 8.005

-1.3%

2:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 9wald9 who wrote (432)	2/23/2005 11:50:48 PM
From: 9wald9	Read Replies (1) of 557

Targeted Genetics Announced Preliminary Safety Data From Phase I HIV Vaccine Trial SEATTLE - PRNewswire-FirstCall - Feb. 22 SEATTLE, Feb. 22 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation today reported preliminary results from a Phase I trial of tgAAC09, an investigational recombinant adeno-associated viral vector (rAAV)-based HIV/AIDS vaccine candidate, enrolling healthy volunteers who are not infected with HIV. The trial is being conducted in Belgium, Germany and India. The Phase I trial is the first ever to test a rAAV-based vaccine and is primarily designed to evaluate safety and tolerability of the vaccine at escalating dose levels. The study is also designed to evaluate immune responses following vaccination. No safety concerns were identified and the vaccine was well tolerated. In addition, a single administration of the vaccine at the doses evaluated in this initial study did not elicit significant immune responses.... (None had been expected at that dosage as there had been none seen in animal testing at that dosage per CEO Parker in her 2/23/2005 presentation.) TGEN closed today at $1.49 no change V 214.3k Market Cap 121.62m

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next